Applicants: Luc Farmer et al.
Application No.: 10/809,944

AMENDMENTS TO THE CLAIMS

Please replace all prior versions and listings of claims with the amended claims as follows:

1. (Currently amended) A compound of formula (I):



I

or a pharmaceutically acceptable salt thereof, wherein:

R^1 and R^2 are each independently R, halogen, CN, NO_2, or TR~~, or R^1 and R^2 taken together form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5- or 6-membered ring having 0-3 heteroatoms independently selected from N, O, or S~~;

T is an optionally substituted C_1-C_4 alkylidene chain wherein up to two methylene units of T are optionally and independently replaced by O, N(R), C(O), S, SO, or SO_2;

Ar^1 is an optionally substituted ring selected from: an aryl group selected from a 5-6 membered monocyclic or an 8-10 membered bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 3-8-membered saturated or partially unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8-10-membered saturated or partially unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein Ar^1 is optionally substituted at one or more carbon atoms with 0-5 occurrences of $-Q-R^5$, and at one or more substitutable nitrogen atoms with $-R^6$ and each occurrence of R^6 is independently R', -COR', $-CO_2(C_{1-6}$ aliphatic), $-CON(R')_2$, $-SO_2N(R')_2$, or $-SO_2R'$;

Applicants: Luc Farmer et al.
Application No.: 10/809,944

R^3 is ~~and R^4 are each independently~~ Z-R^7;

R^4 is hydrogen;

each occurrence of Q and Z is independently a bond or an optionally substituted C_1-C_6 alkylidene chain wherein up to two non-adjacent methylene units of Q and up to three non-adjacent methylene units of Z are optionally replaced by CO, CO_2, COCO, CONR, OCONR, NRNR, NRNRCO, NRCO, $NRCO_2$, NRCONR, SO, SO_2, $NRSO_2$, SO_2NR, $NRSO_2NR$, O, S, or NR;

each occurrence of R^5 and R^7 is independently R', halogen, NO_2, CN, OR', SR', $N(R')_2$, NR'C(O)R', NR'C(O)$N(R')_2$, NR'CO_2R', C(O)R', CO_2R', OC(O)R', C(O)$N(R')_2$, OC(O)$N(R')_2$, SOR', SO_2R', $SO_2N(R')_2$, NR'SO_2R', NR'$SO_2N(R')_2$, $PO(OR')_2$, C(O)C(O)R', or $C(O)CH_2C(O)R'$, or two adjacent occurrences of Q-R^5, taken together with the atoms to which they are bound, form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5-8-membered ring having 0-3 heteroatoms selected from nitrogen, oxygen, or sulfur; and

each occurrence of R is independently hydrogen or an optionally substituted C_{1-6} aliphatic group; and each occurrence of R' is independently hydrogen or an optionally substituted group selected from C_{1-8} aliphatic, C_{6-10} aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 3-10 ring atoms, or wherein two occurrences of R taken together, R and R' taken together, or two occurrences of R' taken together, form an optionally substituted saturated, partially unsaturated, or fully unsaturated 3-8 membered ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur[[;]]

~~provided that :~~

~~when R^1 and R^2 are both hydrogen, R^3 is hydrogen, R^4 is CN, or~~

~~when R^1 and R^2 are both hydrogen, R^3 is NH_2, R^4 is CN,~~

~~then Ar^1 is not phenyl or pyridyl substituted with one or two occurrences of Cl, Me, CH_2NRR', C(O)NRR', or SO_2NRR', wherein R and R' taken together~~

~~form an optionally substituted saturated 6- or 7-membered ring having 1 or 2 heteroatoms independently selected from nitrogen or oxygen.~~

2. (Original) The compound of claim 1, wherein Ar^1 are optionally substituted rings selected from:

(a) a phenyl, indanyl, or naphthyl ring;

(b) a 5-6 membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or

(c) a 5-6 membered monocyclic or 9-10 membered bicyclic heteroaryl ring having 1-3 heteroatoms independently selected from oxygen, nitrogen, or sulfur.

3. (Original) The compound of claim 1, wherein Ar^1 are optionally substituted rings selected from:

(a) a phenyl ring;

(b) a 5-6 membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or

(c) a 5-6 membered monocyclic heteroaryl ring having 1-3 heteroatoms independently selected from oxygen, nitrogen, or sulfur.

4. (Original) The compound of claim 1, wherein Ar^1 is selected from any one of **a-bb**:



a



b



c



d

Applicants: Luc Farmer et al.
Application No.: 10/809,944



Applicants: Luc Farmer et al.
Application No.: 10/809,944

y **z** **aa** **bb**

wherein x is 0-5.

5. (Original) The compound of claim 1, wherein Ar^1 is optionally substituted phenyl, pyrimidinyl, or pyridyl.

6. (Original) The compound of claim 1, wherein Ar^1 is phenyl and is substituted with two (x = 2) or three (x = 3) occurrences of $Q\text{-}R^5$ and Ar^1 is:



or


wherein each occurrence of QR^5 is independently CH_2halogen, halogen, CH_2CN, CN, CH_2CO_2R', CO_2R', CH_2COR', COR', R', CH_2NO_2, NO_2, CH_2OR', OR', CH_2SR', SR', haloalkyl, $CH_2SO_2N(R')_2$, $SO_2N(R')_2$, $CH_2N(R')_2$, $N(R')_2$, NHCOR', CH_2NHCOR', $CH_2PO(OR')_2$, $PO(OR')_2$.

7. (Original) The compound of claim 1, wherein <u>each</u> Q is independently ~~a bond or is~~ an optionally substituted C_1-C_4 alkylidene chain wherein up to two non-adjacent methylene units of Q are optionally replaced by CO, CO_2, CONR, OCONR, NRCO, $NRCO_2$, $NRSO_2$, SO_2NR, O, S, or NR; and each occurrence of R^5 is independently selected from R', halogen, NO_2, CN, OR', SR', $N(R')_2$, $NR'C(O)R'$, $NR'C(O)N(R')_2$, $NR'CO_2R'$, C(O)R', CO_2R', $OC(O)R'$, $C(O)N(R')_2$, $OC(O)N(R')_2$, SOR', SO_2R', $SO_2N(R')_2$, $NR'SO_2R'$, $NR'SO_2N(R')_2$, $PO(OR')_2$, C(O)C(O)R', or $C(O)CH_2C(O)R'$, and x is 0, 1, 2, or 3.

Applicants: Luc Farmer et al.
Application No.: 10/809,944

8. (Original) The compound of claim 1, wherein Q-R^5 substituents on Ar^1 are CH_2halogen, halogen, CH_2CN, CN, CH_2CO_2R', CO_2R', CH_2COR', COR', R', CH_2NO_2, NO_2, CH_2OR', OR', CH_2SR', SR', haloalkyl, $CH_2SO_2N(R')_2$, $SO_2N(R')_2$, $CH_2N(R')_2$, $N(R')_2$, NHCOR', CH_2NHCOR', $CH_2PO(OR')_2$, $PO(OR')_2$, or two adjacent occurrences of Q-R^5, taken together with the atoms to which they are bound, form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5-8-membered ring having 0-3 heteroatoms selected from nitrogen, oxygen, or sulfur.

9. (Original) The compound of claim 1, wherein Q-R^5 substituents on Ar^1 are fluoro, iodo, chloro, bromo, $COCH_3$, CO_2CH_3, C_{1-4}alkyl, NH_2, CH_2NH_2, NHMe, CH_2NHMe, $N(Me)_2$, $CH_2N(Me)_2$, $N(Et)_2$, $CH_2N(Et)_2$, NH(phenyl), $CO(C_{1-4}alkyl)$, $CH_2CO(C_{1-4}alkyl)$, $NHCO(C_{1-4}alkyl)$, $CH_2NHCO(C_{1-4}alkyl)$, CN, CH_2CN, OH, C_{1-4}alkoxy, optionally substituted benzyloxy, optionally substituted phenyloxy, CF_3, SO_2NH_2, SO_2NHMe, optionally substituted SO_2(phenyl), $SO_2(C_{1-4}alkyl)$, $CONH_2$, $CH_2PO(OR')_2$, or an optionally substituted group selected from a saturated, partially unsaturated, or fully unsaturated 5- or 6-membered ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

10. (Currently amended) The compound of claim 1, wherein R^1 and R^2 groups of formula I are each independently hydrogen, $N(R)_2$, SR, OR~~, or TR, or R^1 and R^2, taken together form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5-membered ring having 0-2 heteroatoms independently selected from N, O, or S~~.

11. (Currently amended) The compound of claim 1, wherein R^1 and R^2 groups are each independently hydrogen, OH, CH_3, CH_2CH_3, OCH_3, CH_2OH, CH_2OCH_3, CH_2NH_2, CH_2NHCH_3, NH_2, or CH_2NH_2~~, or R^1 and R^2, taken together, form a fused optionally substituted pyrrolyl, pyrazolyl, or imidazolyl ring~~.

Applicants: Luc Farmer et al.
Application No.: 10/809,944

12. (Currently amended) The compound of claim 1, wherein R^3 is ~~and R^4 are each independently~~ Z-R^7 wherein Z is a bond or an optionally substituted C_{1-4} [[C_{0-4}]] alkylidene chain wherein one methylene unit of Z is optionally replaced by O, NR, NRCO, $NRCO_2$, $NRSO_2$, CONR, C(O), C(O)O, and wherein R^7 is selected from halogen, CN, $N(R')_2$, NHCOR', or R', ~~or wherein R^3 and R^4, taken together form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5- or 6-membered ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur~~.

13. (Currently amended) The compound of claim 1, wherein R^3 is ~~and R^4 are each independently~~ hydrogen, CN, halogen, OH, SH, NH_2, CO_2H, COH, $CONH_2$, SO_2NH_2, NO_2, or $(CH_2)_nNRR^7$, wherein R and R^7, taken together with the nitrogen atom to which they are bound, form an optionally substituted 3-8-membered saturated or partially unsaturated ring having 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur, ~~or R^3 and R^4, taken together with the atoms to which they are bound, form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5- or 6-membered ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and n is 0, 1, 2, 3, 4, or 5~~.

14. (Currently amended) The compound of claim 1, wherein ~~one of~~ R^3 ~~or R^4 is hydrogen, and the other of R^3 or R^4~~ is $(CH_2)_n$halogen, $(CH_2)_nCN$, $(CH_2)_nOR^7$, $(CH_2)_nNRR^7$, $(CH_2)_nC(O)R^7$, $(CH_2)_nC(O)R^7$ $(CH_2)_nCH_3$, $(CH_2)_nC(O)NRR^7$, $(CH_2)_nSR^7$, wherein R^7 is hydrogen, $(CH_2)_mN(R')_2$, C_1-C_4alkyl, an optionally substituted 5- or 6-membered aryl, ~~aralkyl,~~ or heteroaryl, ~~or heteroaralkyl~~ group, or R and R^7, taken together with the nitrogen atom to which they are bound form an optionally substituted 3-8-membered saturated or partially unsaturated ring having 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur, wherein n is 0 or 1 and m is 0 or 1.

Applicants: Luc Farmer et al.
Application No.: 10/809,944

15. (Original) The compound of claim 14, wherein R^3 is hydrogen.

16. (Canceled)

17. (Currently amended) The compound of claim 1, having one of formulae ~~formulas~~ **[[I-A-i,]] I-A-ii, [[I-B-i,]] I-B-ii, [[I-C-i,]] I-C-ii, [[I-D-i,]] [[or]] I-E-i, or I-F-ii:**



~~I-A-i~~



I-A-ii



~~I-B-i~~



I-B-ii





Applicants: Luc Farmer et al.
Application No.: 10/809,944

~~I-C-i~~



I-C-ii



~~I-D-i~~



I-E-i



~~I-F-i~~

I-F-ii

18. (Original) The compound of claim 17, wherein Ar^1 is:

(a) a phenyl, indanyl, or naphthyl ring;

(b) a 5-6 membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or

(c) a 5-6 membered monocyclic or 9-10 membered bicyclic heteroaryl ring having 1-3 heteroatoms independently selected from oxygen, nitrogen, or sulfur.

19. (Original) The compound of claim 17, wherein Ar^1 is:

(a) a phenyl ring;

(b) a 5-6 membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or

Applicants: Luc Farmer et al.
Application No.: 10/809,944

(c) a 5-6 membered monocyclic heteroaryl ring having 1-3 heteroatoms independently selected from oxygen, nitrogen, or sulfur.

20. (Currently amended) The compound of claim 17, wherein Ar^1 is any one of **a-bb**:





wherein ~~Q and R^5 are as defined generally above and in subsets herein, and~~ x is 0-5.

21. (Original) The compound of claim 17, wherein Ar^1 is phenyl, pyrimidinyl, or pyridyl.

22. (Original) The compound of claim 17, wherein Ar^1 is phenyl and is substituted with two (x = 2) or three (x = 3) occurrences of $Q\text{-}R^5$ and Ar^1 is:



wherein each occurrence of QR^5 is independently CH_2halogen, halogen, CH_2CN, CN, CH_2CO_2R', CO_2R', CH_2COR', COR', R', CH_2NO_2, NO_2, CH_2OR', OR', CH_2SR', SR', haloalkyl, $CH_2SO_2N(R')_2$, $SO_2N(R')_2$, $CH_2N(R')_2$, $N(R')_2$, NHCOR', CH_2NHCOR', $CH_2PO(OR')_2$, $PO(OR')_2$.

Applicants: Luc Farmer et al.
Application No.: 10/809,944

23. (Currently amended) The compound of claim 17, wherein Ar^1 is optionally substituted phenyl and compounds have one of formulae ~~formulas~~ [[**I-A-i,**]] **I-A-ii,** [[**I-B-i,**]] **I-B-ii,** [[**I-C-i,**]] **I-C-ii,** [[**I-D-i,**]] [[or]] **I-E-i, or I-F-ii:**



~~**II-A-i**~~



II-A-ii



~~**II-B-i**~~



II-B-ii



~~**II-C-i**~~



II-C-ii

Applicants: Luc Farmer et al.
Application No.: 10/809,944



~~II-D-i~~



II-E-i



~~II-F-i~~



II-F-ii

where x is 0-5.

24. (Original) The compound of claim 23, wherein each occurrence of Q is independently a bond or is an optionally substituted C_1-C_4 alkylidene chain wherein up to two non-adjacent methylene units of Q are optionally replaced by CO, CO_2, CONR, OCONR, NRCO, $NRCO_2$, $NRSO_2$, SO_2NR, O, S, or NR; and each occurrence of R^5 is independently selected from R', halogen, NO_2, CN, OR', SR', $N(R')_2$, NR'C(O)R', NR'C(O)N(R')$_2$, NR'CO_2R', C(O)R', CO_2R', OC(O)R', C(O)N(R')$_2$, OC(O)N(R')$_2$, SOR', SO_2R', $SO_2N(R')_2$, NR'SO_2R', NR'$SO_2N(R')_2$, $PO(OR')_2$, C(O)C(O)R', or C(O)CH_2C(O)R', and x is 0, 1, 2, or 3.

Applicants: Luc Farmer et al.
Application No.: 10/809,944

25. (Original) The compound of claim 23, wherein each occurrence of Q-R^5 is independently CH_2halogen, halogen, CH_2CN, CN, CH_2CO_2R', CO_2R', CH_2COR', COR', R', CH_2NO_2, NO_2, CH_2OR', OR', CH_2SR', SR', haloalkyl, $CH_2SO_2N(R')_2$, $SO_2N(R')_2$, $CH_2N(R')_2$, $N(R')_2$, NHCOR', CH_2NHCOR', $CH_2PO(OR')_2$, $PO(OR')_2$, or two adjacent occurrences of Q-R^5, taken together with the atoms to which they are bound, form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5-8-membered ring having 0-3 heteroatoms selected from nitrogen, oxygen, or sulfur.

26. (Original) The compound of claim 23, wherein each occurrence of Q-R^5 is independently fluoro, iodo, chloro, bromo, $COCH_3$, CO_2CH_3, C_{1-4}alkyl, NH_2, CH_2NH_2, NHMe, CH_2NHMe, $N(Me)_2$, $CH_2N(Me)_2$, $N(Et)_2$, $CH_2N(Et)_2$, NH(phenyl), $CO(C_{1-4}alkyl)$, $CH_2CO(C_{1-4}alkyl)$, $NHCO(C_{1-4}alkyl)$, $CH_2NHCO(C_{1-4}alkyl)$, CN, CH_2CN, OH, C_{1-4}alkoxy, optionally substituted benzyloxy, optionally substituted phenyloxy, CF_3, SO_2NH_2, SO_2NHMe, optionally substituted SO_2(phenyl), $SO_2(C_{1-4}alkyl)$, $CONH_2$, $CH_2PO(OR')_2$, or an optionally substituted group selected from a saturated, partially unsaturated, or fully unsaturated 5- or 6-membered ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

27. (Currently amended) The compound of claim 23, wherein R^1 and R^2 are each independently hydrogen, $N(R)_2$, SR, OR, or TR~~, or R^1 and R^2, taken together form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5-membered ring having 0-2 heteroatoms independently selected from N, O, or S~~.

28. (Currently amended) The compound of claim 27, wherein R^1 and R^2 are each independently hydrogen, OH, CH_3, CH_2CH_3, OCH_3, CH_2OH, CH_2OCH_3, CH_2NH_2, CH_2NHCH_3, NH_2, or CH_2NH_2~~, or R^1 and R^2, taken together, form a fused optionally substituted pyrrolyl, pyrazolyl, or imidazolyl ring~~.

Applicants: Luc Farmer et al.
Application No.: 10/809,944

29. (Original) The compound of claim 23, wherein R^3 is Z-R^7, wherein Z is a bond or is an optionally substituted C_{1-4} [[C_{1-4}]] alkylidene chain wherein one methylene unit of Z is optionally replaced by O, NR, NRCO, $NRCO_2$, $NRSO_2$, CONR, C(O), C(O)O, and wherein R^7 is halogen, CN, $N(R')_2$, NHCOR', or R'.

30. (Original) The compound of claim 23, wherein R^3 is $(CH_2)_n$halogen, $(CH_2)_nCN$, $(CH_2)_nOR^7$, $(CH_2)_nNRR^7$, $(CH_2)_nC(O)R^7$, $(CH_2)_nC(O)R^7$ $(CH_2)_nCH_3$, $(CH_2)_nC(O)NRR^7$, $(CH_2)_nSR^7$, wherein R^7 is $(CH_2)_mN(R')_2$, C_1-C_4alkyl, an optionally substituted 5- or 6-membered aryl~~, aralkyl,~~ or heteroaryl~~, or heteroaralkyl~~ group, or R and R^7, taken together with the nitrogen atom to which they are bound form an optionally substituted 3-8-membered saturated or partially unsaturated ring having 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur, n is 0 or 1, and m is 0 or 1.

31-33. (Canceled)

34. (Currently amended) The compound of claim 23, wherein compounds have one of formulas **II-A-ii, II-B-ii, II-C-ii**, or **II-F-ii** and one or more of the compound variables are defined as:

a) x is 0, 1, 2, or 3, and Q-R^5 is CH_2halogen, halogen, CH_2CN, CN, CH_2CO_2R', CO_2R', CH_2COR', COR', R', CH_2NO_2, NO_2, CH_2OR', OR', CH_2SR', SR', haloalkyl, $CH_2SO_2N(R')_2$, $SO_2N(R')_2$, $CH_2N(R')_2$, $N(R')_2$, NHCOR', CH_2NHCOR', $CH_2PO(OR')_2$, $PO(OR')_2$, or Q-R^5, taken together with the atoms to which they are bound, form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5-8-membered ring having 0-3 heteroatoms selected from nitrogen, oxygen, or sulfur;

b) R^1 and R^2 are each independently hydrogen, $N(R)_2$, SR, OR, or TR~~, or R^1 and R^2, taken together form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5-membered ring having 0-2 heteroatoms independently selected from N, O, or S~~: and

Applicants: Luc Farmer et al.
Application No.: 10/809,944

c) R^4 is $(CH_2)_n$halogen, $(CH_2)_nCN$, $(CH_2)_nOR^7$, $(CH_2)_nNRR^7$, $(CH_2)_nC(O)R^7$, $(CH_2)_nC(O)R^7$ $(CH_2)_nCH_3$, $(CH_2)_nC(O)NRR^7$, $(CH_2)_nSR^7$, wherein R^7 is $(CH_2)_mN(R')_2$, C_1-C_4alkyl, an optionally substituted 5- or 6-membered aryl, aralkyl, heteroaryl, or heteroaralkyl group, or R and R^7, taken together with the nitrogen atom to which they are bound form an optionally substituted 3-8-membered saturated or partially unsaturated ring having 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur, n is 0 or 1, and m is 0 or 1.

35. (Canceled)

36. (Currently amended) The compound of claim 1, selected from:



I-1



I-2



I-3



I-4



I-5



I-6

Applicants: Luc Farmer et al.
Application No.: 10/809,944



I-7



I-8



I-9



I-10



I-11



I-12



I-13



I-14



I-15

Applicants: Luc Farmer et al.
Application No.: 10/809,944



I-16



I-17



I-18



I-19



I-20



I-21



I-22



I-23



I-24

Applicants: Luc Farmer et al.
Application No.: 10/809,944



I-25



I-26



I-27



I-28



I-29



I-30



I-31



I-32



I-33



I-34



I-35



I-36

Applicants: Luc Farmer et al.
Application No.: 10/809,944



I-37



I-38



I-39



I-40



I-41



I-42



I-43



I-44



I-45

Applicants: Luc Farmer et al.
Application No.: 10/809,944



I-46



I-47



I-48



I-49



I-50



I-51



I-52



I-53



I-54

Applicants: Luc Farmer et al.
Application No.: 10/809,944



I-55



I-56



I-57



I-58



~~I-59~~



I-60



I-61



I-62



I-63

Applicants: Luc Farmer et al.
Application No.: 10/809,944



I-64



I-65



I-66



I-67



I-68

37. (Original) A composition comprising a compound of claim 1, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

38. (Original) The composition of claim 37, wherein the compound is in an amount to detectably inhibit SYK, or ZAP-70 protein kinase activity.

39. (Original) The composition of claim 37, additionally comprising a therapeutic agent selected from an anti-inflammatory agent, an anti-proliferative agent, an immunomodulatory or immunosuppressive agent, or an agent for treating immunodeficiency disorders.

Applicants: Luc Farmer et al.
Application No.: 10/809,944

40. (Currently amended) A method of inhibiting SYK or ZAP-70 kinase activity in~~:~~

~~(a) a patient; or~~

~~(b)~~ a biological sample;

which method comprises ~~administering to said patient, or~~ contacting said biological sample with:

a) a composition of claim 37; or

b) a compound of claim 1.

41. (Currently amended) A method of treating or lessening the severity of ~~treatment or lessening the severity of~~ lepromatous leprosy ~~an immunodeficiency disorder~~, atopical dermatitis, contact dermatitis, seborrhoetic dermatitis, Lichen planus, Pemphigus, bullous Pemphigus, epidermolysis bullosa, urticaria, angiodermas, vasculitides, erythemas, cutaneous eosinophilias, uveitis, Alopecia, areata, vernal conjunctivitis, eosinophilia fasciitis ~~inflammatory disease~~, Coeliac disease, proctitis, eosinophilic gastro-enteritis, mastocytosis, pancreatitis, Crohn's disease, ulcerative colitis, migraine, rhinitis, ~~allergic disease~~, multiple sclerosis, lupus erythematosus, rheumatoid arthritis, type I diabetes, psoriasis, seronegative spondyloarthropathis, Behcet's disease, Sjogren's syndrome, systemic sclerosis, Hashimoto's thyroiditis, myasthenia gravis, nephrotic syndrome, idiopathic thrombocytopenia purpura, hyper IgE syndrome ~~autoimmune disease~~, leukemia, lymphoma, Sezary syndrome, restenosis following angioplasty, atherosclerosis ~~proliferative disorder~~, allograft rejection, graft versus host disease ~~immunologically mediated disease~~, or asthma, ~~respiratory disorder,~~ comprising the step of administering to said patient:

a) a composition of claim 37; or

b) a compound of claim 1.

42. (Currently amended) The method according to claim 41, comprising the additional step of administering to said patient an additional therapeutic agent selected

from an anti-inflammatory agent, an anti-proliferative agent, an immunomodulatory or immunosuppressive agent, or an agent for treating immunodeficiency disorders, wherein: said additional therapeutic agent is appropriate for the disease being treated[[;]] and ~~said additional therapeutic agent~~ is administered together with said composition as a single dosage form or separately from said composition as part of a multiple dosage form.

43. (Currently amended) The method according to claim 41, wherein the disease is multiple sclerosis, lupus erythematosus, rheumatoid arthritis, type I diabetes, psoriasis, seronegative spondyloarthropathis, Behcet's disease, Sjogren's syndrome, systemic sclerosis, Hashimoto's thyroiditis, myasthenia gravis, nephrotic syndrome, idiopathic thrombocytopenia purpura, or hyper IgE syndrome ~~an immune disorder~~.

44. (Original) The method according to claim 41, wherein the disease is asthma.